Greg Marshall, Ph.D.
Dr. Marshall earned his Ph.D. in Genetics from the University of Florida College of Medicine and has been with OneVax since 2013. He is principal investigator on two Phase 1 SBIR grants, one R21 grant, and one STTR grant awarded to OneVax from the NIAID of the NIH. His research focuses on toxicological assessment of our microparticle/hydrogel therapy and determining the efficacy of our nanoparticle/regulatory T Cell therapy in preventing diabetic onset.
Chun-Wei Wang, Ph. D.
Dr. Wang earned his Ph.D. inPhysics / Biophotonics at the University of Alabama at Birmingham. He joined OneVax in 2017.
Ben Looney, Ph.D.
Dr. Looney earned his Ph.D. in Immunology & Microbiology from the University of Florida College of Medicine. He joined OneVax in 2017